News for Amicus Therapeutics, Inc. (FOLD.MX)

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsAndrew Faughnan - Vice President of...

Summary Amicus Therapeutics Inc (FOLD), a global biotechnology company dedicated to developing innovative medicines for rare diseases, has announced a conferenc

Key Takeaways: Amicus Therapeutics (FOLD) receives a rating boost from Morgan Stanley to "Overweight." Potential growth anticipated from its new Pompe di

Morgan Stanley has raised its rating for Amicus Therapeutics (FOLD) from Equal Weight to Overweight, accompanied by an increased price target from $102 to $108.

Morgan Stanley has upgraded Amicus Therapeutics (FOLD) from an "Equal Weight" to an "Overweight" rating. The investment firm has set a price target for the stoc

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On June 25, Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported that it received approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adults with late-onset Pompe disease (LOPD) from Japan’s Ministry of Health, Labour and Welfare (MHLW). […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 13 Best Healthcare Stocks to Buy Under $10. On May 1, analyst Ritu Baral from TD Cowen maintained a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD), keeping the price target at $20.00. The analyst based the rating on the company’s future growth potential and strategic positioning, stating that Amicus […]

PR NewswirePHILADELPHIA, July 10, 2025 PHILADELPHIA, July 10, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Amicus Therapeutics,

On July 2, 2025, Redmile Group, LLC (Trades, Portfolio) executed a significant transaction involving Fate Therapeutics Inc. The firm added 5,068,633 shares of F

Summary Amicus Therapeutics Inc (FOLD) announced on June 3, 2025, the publication of a post-hoc analysis from the PROPEL study in the journal "Muscle and Nerve.

Amicus Therapeutics (FOLD) has unveiled a publication detailing a post-hoc analysis from the PROPEL study, focusing on adults with late-onset Pompe disease. Thi

PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics ( FOLD), today announced the publication of a post-hoc analysis of data from the ERT-e

Summary Amicus Therapeutics Inc (FOLD), a global biotechnology company dedicated to developing innovative medicines for rare diseases, announced on May 30, 2025

On May 16, 2025, Redmile Group, LLC (Trades, Portfolio) executed a notable transaction involving Atara Biotherapeutics Inc. The firm added 263,506 shares of Ata

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Amicus Therapeutics, Inc.

In a recent update, UBS analyst Karl Chalabala has maintained a \

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsAndrew Faughnan - Vice President of...

Revenue: $125.2 million for Q1 2025, falling short of the estimated $135.86 million, yet marking a 15% increase year-over-year at constant exchange rates.Earni

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]